gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CGCHealthcarePharmaceuticals

Canopy Growth Corporation Common Shares (CGC)

$0.7517+6.37%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.75▼ 33.48% in range
Nov 4, 2025Low $0.65 · High $1.92Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Canopy Growth Corporation Common Shares closed at $0.75 on Nov 4, up 6.37%, 60.8% below its 52-week closing high. Volume of 2.7M shares was 1.05× its 20-day average (close to normal).

Split-adjusted performance: -15.6% over one month, -34.6% over six months, -37.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $57.13M, up 7.8% from a year earlier, with a net margin of -18.0%.

Short interest was 31.6M shares at the Oct 15 settlement, up 16.1% from the prior report (7.5% of float, 10.8 days to cover).

Market cap$318.0M423.0M shares
Revenue · quarter$57.1M+7.8% YoY
Diluted EPS$-0.02—
P/E · TTM—P/S 1.3×
Net margin-18.0%Gross 27.4%
Dividend yieldNone$0.24 last paid
52-week range0.65 – 1.92−60.8% from high
Volume2.7M1.05× 20-day avg
Volatility · 60d42.5%Annualised
Short % of float7.5%10.8 days to cover
Net cash$67.9MCash $236.9M
Next earnings—Not scheduled
Split-adjusted performance
1W +11.9%1M −15.6%3M −19.4%6M −34.6%YTD −34.1%1Y −37.4%3Y −85.5%5Y −99.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum39
Revenue growth54
Net margin58
Value (low P/E)—
Size55

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short31.6M+16.1% vs prior
Days to cover10.8Settled Oct 15
% of float7.5%
Short vol. 10d45.8%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CGCCanopy Growth$0.7517+6.37%−34.6%+7.8%−18.0%—$318.0M
BNTCBenitec Biopharma$9.28+10.48%−26.2%———$323.8MCompare
PRLDPrelude Therapeutics Incorporated$4.08+7.94%−15.7%—−244.1%—$325.6MCompare
ENTAEnanta Pharmaceuticals$10.65+2.70%−30.1%−21.6%−135.8%—$310.2MCompare
CYPHCypherpunk Technologies$2.87+10.38%+154.0%———$309.3MCompare
ARCTArcturus Therapeutics Holdings$10.87+13.94%+19.1%−89.5%−803.8%—$309.0MCompare
SPRYARS Pharmaceuticals$3.050.00%−67.1%+114.2%−185.2%—$303.3MCompare
EBSEmergent Biosolutions$5.90−5.60%−35.2%−52.4%−29.7%—$302.5MCompare
TTRXTurn Therapeutics$9.80+3.05%+158.2%———$297.6MCompare

News about Canopy Growth

All news →
Canopy Growth vs. Tilray Brands: Quarterly Revenue Scale and Consistency in CannabisThe Motley Fool · 5d agoNeutralCanopy Growth Corporation (CGC) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research · Oct 27, 2026▼ NegativeCanopy Growth Corporation (CGC) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research · Oct 21, 2026▼ NegativeTrump's Marijuana Order Is Stuck at the DEA. Here's What That Means for Canopy Growth.The Motley Fool · Oct 18, 2026▼ NegativeCanopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026?The Motley Fool · Oct 15, 2026Neutral

Quick answers

What does Canopy Growth Corporation Common Shares do?
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia.
What is CGC's market cap?
$318M, based on the Nov 4 close of $0.75.
Does Canopy Growth Corporation Common Shares pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CGC is sold short?
31.6M shares, 7.5% of float, as of Oct 15, 2026.
What sector is CGC in?
Healthcare, in the Pharmaceuticals industry.

About Canopy Growth

Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.

HQ: Smith Falls, A61,128 employeesListed Apr 7, 2014canopygrowth.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology